应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SNDX Syndax Pharmaceuticals, Inc.
已收盘 07-14 16:00:00 EDT
9.85
+0.26
+2.71%
盘后
9.50
-0.35
-3.52%
18:35 EDT
最高
9.87
最低
9.53
成交量
175.13万
今开
9.57
昨收
9.59
日振幅
3.55%
总市值
8.48亿
流通市值
7.58亿
总股本
8,605万
成交额
1,709万
换手率
2.28%
流通股本
7,695万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.19%报9.72美元
市场透视 · 07-10
Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.19%报9.72美元
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.26%报9.21美元
市场透视 · 07-09
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.26%报9.21美元
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.12%
市场透视 · 07-02
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.12%
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.09%报9.50美元
市场透视 · 06-30
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.09%报9.50美元
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.00%报9.35美元
市场透视 · 06-26
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.00%报9.35美元
Syndax Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.06%
市场透视 · 06-13
Syndax Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.06%
Syndax Pharmaceuticals, Inc.盘中异动 急速拉升5.65%
市场透视 · 06-06
Syndax Pharmaceuticals, Inc.盘中异动 急速拉升5.65%
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.03%
市场透视 · 06-02
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.03%
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.02%
市场透视 · 05-23
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.02%
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.01%报11.10美元
市场透视 · 05-21
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.01%报11.10美元
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨8.60%
市场透视 · 05-20
Syndax Pharmaceuticals, Inc.盘中异动 股价大涨8.60%
Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.17%报8.80美元
市场透视 · 05-15
Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.17%报8.80美元
Syndax Pharmaceuticals, Inc.盘中异动 大幅下挫5.00%报9.68美元
市场透视 · 05-14
Syndax Pharmaceuticals, Inc.盘中异动 大幅下挫5.00%报9.68美元
Syndax Pharmaceuticals, Inc.2025财年第一财季实现净利润-84.85百万美元,同比减少17.20%
市场透视 · 05-10
Syndax Pharmaceuticals, Inc.2025财年第一财季实现净利润-84.85百万美元,同比减少17.20%
Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.08%报10.10美元
市场透视 · 05-07
Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.08%报10.10美元
Scotiabank:维持Syndax Pharmaceuticals(SNDX.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由16.00美元调整至17.00美元。
金融界 · 05-06
Scotiabank:维持Syndax Pharmaceuticals(SNDX.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由16.00美元调整至17.00美元。
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.27%报12.86美元
市场透视 · 05-06
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.27%报12.86美元
Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.11%报12.54美元
市场透视 · 04-22
Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.11%报12.54美元
Syndax Pharmaceuticals, Inc.盘中异动 下午盘急速拉升5.04%报11.05美元
市场透视 · 04-11
Syndax Pharmaceuticals, Inc.盘中异动 下午盘急速拉升5.04%报11.05美元
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.07%
市场透视 · 03-10
Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.07%
加载更多
公司概况
公司名称:
Syndax Pharmaceuticals, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,正在开发癌症疗法的创新管道。该公司正在开发revumenib,这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂,用于治疗KMT2A重排或KMT2AR,也称为混合谱系白血病重排或MLLR,包括急性淋巴细胞白血病或ALL在内的急性白血病,以及急性髓细胞白血病或AML,以及necleophosmin 1,也称为NPM1,突变AML。
发行价格:
--
{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals, Inc. ","latestPrice":9.85,"timestamp":1752523200000,"preClose":9.59,"halted":0,"volume":1751293,"hourTrading":{"tag":"盘后","latestPrice":9.5033,"preClose":9.85,"latestTime":"18:35 EDT","volume":40750,"amount":401234.2686,"timestamp":1752532548559},"delay":0,"floatShares":76947363,"shares":86047449,"eps":-3.85741,"marketStatus":"已收盘","change":0.26,"latestTime":"07-14 16:00:00 EDT","open":9.57,"high":9.87,"low":9.53,"amount":17088565.436705,"amplitude":0.035454,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.85741,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752566400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":9.59,"preHourTrading":{"tag":"盘前","latestPrice":9.53,"preClose":9.59,"latestTime":"09:28 EDT","volume":2010,"amount":19235.49498,"timestamp":1752499680030},"postHourTrading":{"tag":"盘后","latestPrice":9.5033,"preClose":9.85,"latestTime":"18:35 EDT","volume":40750,"amount":401234.2686,"timestamp":1752532548559},"volumeRatio":0.859753,"impliedVol":0.5769,"impliedVolPercentile":0.392},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2550624591","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.19%报9.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550624591","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550624591?lang=zh_cn&edition=full","pubTime":"2025-07-10 23:11","pubTimestamp":1752160294,"startTime":"0","endTime":"0","summary":"北京时间2025年07月10日23时11分,Syndax Pharmaceuticals, Inc.股票出现波动,股价大幅拉升5.19%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.94%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710231135a6a1e5a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710231135a6a1e5a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2550465347","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.26%报9.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550465347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550465347?lang=zh_cn&edition=full","pubTime":"2025-07-09 21:49","pubTimestamp":1752068944,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日21时49分,Syndax Pharmaceuticals, Inc.股票出现波动,股价急速拉升5.26%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.97%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214904a69f9381&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214904a69f9381&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2548818722","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548818722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548818722?lang=zh_cn&edition=full","pubTime":"2025-07-02 22:12","pubTimestamp":1751465539,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日22时12分,Syndax Pharmaceuticals, Inc.股票出现波动,股价快速上涨5.12%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.84%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702221219a4cb6328&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702221219a4cb6328&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2548017512","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.09%报9.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548017512","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548017512?lang=zh_cn&edition=full","pubTime":"2025-07-01 03:37","pubTimestamp":1751312257,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日03时37分,Syndax Pharmaceuticals, Inc.股票出现异动,股价快速拉升5.09%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.30%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070103373795319a43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070103373795319a43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2546324177","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.00%报9.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546324177","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546324177?lang=zh_cn&edition=full","pubTime":"2025-06-26 22:45","pubTimestamp":1750949154,"startTime":"0","endTime":"0","summary":"北京时间2025年06月26日22时45分,Syndax Pharmaceuticals, Inc.股票出现异动,股价快速拉升5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.15%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626224554a4bf61a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626224554a4bf61a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2543634108","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543634108","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543634108?lang=zh_cn&edition=full","pubTime":"2025-06-14 02:31","pubTimestamp":1749839501,"startTime":"0","endTime":"0","summary":"北京时间2025年06月14日02时31分,Syndax Pharmaceuticals, Inc.股票出现波动,股价大幅下跌5.06%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.78%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614023141977e9397&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614023141977e9397&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2541186635","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速拉升5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541186635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541186635?lang=zh_cn&edition=full","pubTime":"2025-06-06 21:40","pubTimestamp":1749217209,"startTime":"0","endTime":"0","summary":"北京时间2025年06月06日21时40分,Syndax Pharmaceuticals, Inc.股票出现异动,股价快速拉升5.65%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.74%。其相关个股中,Eyenovia, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Nucana Plc涨幅较大,Nucana Plc、Eyenovia, Inc.、Glycomimetics, Inc.较为活跃,换手率分别为1530.93%、549.74%、75.77%,振幅较大的相关个股有Silo Pharma, Inc.、Eyenovia, Inc.、Nucana Plc,振幅分别为26.33%、22.29%、16.71%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506062140109774723f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506062140109774723f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2540796381","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540796381","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540796381?lang=zh_cn&edition=full","pubTime":"2025-06-02 21:33","pubTimestamp":1748871207,"startTime":"0","endTime":"0","summary":"北京时间2025年06月02日21时33分,Syndax Pharmaceuticals, Inc.股票出现异动,股价急速上涨5.03%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.39%。其相关个股中,Lyra Therapeutics, Inc.、Oragenics Inc.、Vera Therapeutics, Inc.涨幅较大,Lyra Therapeutics, Inc.、Oragenics Inc.、Plus Therapeutics, Inc.较为活跃,换手率分别为983.85%、590.14%、261.87%,振幅较大的相关个股有Lyra Therapeutics, Inc.、Oragenics Inc.、Nutriband Inc C/Wts ,振幅分别为72.82%、57.67%、41.96%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602213327976e8109&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602213327976e8109&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2537113769","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537113769","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537113769?lang=zh_cn&edition=full","pubTime":"2025-05-23 22:10","pubTimestamp":1748009407,"startTime":"0","endTime":"0","summary":"北京时间2025年05月23日22时10分,Syndax Pharmaceuticals, Inc.股票出现异动,股价急速跳水5.02%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.17%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523221007a6ea67cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523221007a6ea67cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2537932091","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.01%报11.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537932091","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537932091?lang=zh_cn&edition=full","pubTime":"2025-05-21 23:45","pubTimestamp":1747842315,"startTime":"0","endTime":"0","summary":"北京时间2025年05月21日23时45分,Syndax Pharmaceuticals, Inc.股票出现波动,股价大幅上涨5.01%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.25%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505212345169760f539&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505212345169760f539&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2536645150","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨8.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536645150","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536645150?lang=zh_cn&edition=full","pubTime":"2025-05-20 21:31","pubTimestamp":1747747877,"startTime":"0","endTime":"0","summary":"北京时间2025年05月20日21时31分,Syndax Pharmaceuticals, Inc.股票出现异动,股价大幅拉升8.60%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.07%。其相关个股中,Neuraxis, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,Polyrizon Ltd.、Eyenovia, Inc.、Neuraxis, Inc.较为活跃,换手率分别为1207.62%、1177.07%、469.63%,振幅较大的相关个股有Neuraxis, Inc.、Xortx Therapeutics Inc.、Armata Pharmaceuticals, Inc.,振幅分别为24.23%、13.98%、13.06%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520213117a4857dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520213117a4857dd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2535827907","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.17%报8.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535827907","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535827907?lang=zh_cn&edition=full","pubTime":"2025-05-15 22:28","pubTimestamp":1747319313,"startTime":"0","endTime":"0","summary":"北京时间2025年05月15日22时28分,Syndax Pharmaceuticals, Inc.股票出现波动,股价快速下挫5.17%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.52%。其相关个股中,Nucana Plc、Abpro Holdings, Inc、Scpharmaceuticals Inc.涨幅较大,Nucana Plc、Polyrizon Ltd.、Abpro Holdings, Inc较为活跃,换手率分别为10434.80%、3320.02%、290.99%,振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Nucana Plc、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ,振幅分别为76.92%、49.42%、45.20%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515222834aa2c9008&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515222834aa2c9008&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2535074716","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅下挫5.00%报9.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535074716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535074716?lang=zh_cn&edition=full","pubTime":"2025-05-14 23:32","pubTimestamp":1747236746,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日23时32分,Syndax Pharmaceuticals, Inc.股票出现波动,股价急速下挫5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为1.23%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051423322697599cb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051423322697599cb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2534066426","title":"Syndax Pharmaceuticals, Inc.2025财年第一财季实现净利润-84.85百万美元,同比减少17.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534066426","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534066426?lang=zh_cn&edition=full","pubTime":"2025-05-11 00:01","pubTimestamp":1746892882,"startTime":"0","endTime":"0","summary":"5月11日,Syndax Pharmaceuticals, Inc.公布财报,公告显示公司2025财年第一财季净利润为-84.85百万美元,同比减少17.20%;其中营业收入为20.04百万美元,每股基本收益为-0.98美元。机构评级:截至2025年5月11日,当前有12家机构对Syndax Pharmaceuticals, Inc.目标价做出预测,其中目标均价为35.42美元,其中最低目标价为17.00美元,最高目标价为51.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511000342a4796121&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511000342a4796121&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2533686699","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.08%报10.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533686699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533686699?lang=zh_cn&edition=full","pubTime":"2025-05-08 02:40","pubTimestamp":1746643255,"startTime":"0","endTime":"0","summary":"北京时间2025年05月08日02时40分,Syndax Pharmaceuticals, Inc.股票出现波动,股价快速跳水5.08%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.97%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508024055aa2c8667&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508024055aa2c8667&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2533565415","title":"Scotiabank:维持Syndax Pharmaceuticals(SNDX.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由16.00美元调整至17.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533565415","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533565415?lang=zh_cn&edition=full","pubTime":"2025-05-07 00:11","pubTimestamp":1746547903,"startTime":"0","endTime":"0","summary":"Scotiabank:维持Syndax Pharmaceuticals(SNDX.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由16.00美元调整至17.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07001150176764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SNDX"],"gpt_icon":0},{"id":"2533637900","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.27%报12.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533637900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533637900?lang=zh_cn&edition=full","pubTime":"2025-05-06 21:30","pubTimestamp":1746538256,"startTime":"0","endTime":"0","summary":"北京时间2025年05月06日21时30分,Syndax Pharmaceuticals, Inc.股票出现异动,股价快速跳水5.27%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505062130569750bfe2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505062130569750bfe2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2529809235","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.11%报12.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529809235","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529809235?lang=zh_cn&edition=full","pubTime":"2025-04-22 22:09","pubTimestamp":1745330960,"startTime":"0","endTime":"0","summary":"北京时间2025年04月22日22时09分,Syndax Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.11%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.39%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422220921a6c3e3a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422220921a6c3e3a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2526614610","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘急速拉升5.04%报11.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2526614610","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2526614610?lang=zh_cn&edition=full","pubTime":"2025-04-12 03:23","pubTimestamp":1744399419,"startTime":"0","endTime":"0","summary":"北京时间2025年04月12日03时23分,Syndax Pharmaceuticals, Inc.股票出现异动,股价急速上涨5.04%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为2.13%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法产品线。其候选产品包括 revumenib 和 axatilimab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250412032339a4567bef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250412032339a4567bef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2518278453","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278453","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518278453?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:22","pubTimestamp":1741616534,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时22分,Syndax Pharmaceuticals, Inc.股票出现波动,股价大幅下挫5.07%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.47%。其相关个股中,Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃,换手率分别为3400.89%、719.71%、414.19%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc,振幅分别为41.36%、40.24%、39.34%。Syndax Pharmaceuticals, Inc.公司简介:Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222215a26a3846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222215a26a3846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0656},{"period":"1month","weight":-0.1202},{"period":"3month","weight":-0.1407},{"period":"6month","weight":-0.2685},{"period":"1year","weight":-0.5919},{"period":"ytd","weight":-0.2746}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.037},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0743},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.0641}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,正在开发癌症疗法的创新管道。该公司正在开发revumenib,这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂,用于治疗KMT2A重排或KMT2AR,也称为混合谱系白血病重排或MLLR,包括急性淋巴细胞白血病或ALL在内的急性白血病,以及急性髓细胞白血病或AML,以及necleophosmin 1,也称为NPM1,突变AML。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.047367},{"month":2,"riseRate":0.666667,"avgChangeRate":0.081651},{"month":3,"riseRate":0.555556,"avgChangeRate":0.051247},{"month":4,"riseRate":0.4,"avgChangeRate":0.014629},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019495},{"month":6,"riseRate":0.5,"avgChangeRate":-0.003538},{"month":7,"riseRate":0.6,"avgChangeRate":0.012737},{"month":8,"riseRate":0.555556,"avgChangeRate":0.046113},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.028471},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.074254},{"month":11,"riseRate":0.555556,"avgChangeRate":0.001387},{"month":12,"riseRate":0.444444,"avgChangeRate":0.03326}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals, Inc. ","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Syndax Pharmaceuticals, Inc. ,SNDX,Syndax Pharmaceuticals, Inc. 股票,Syndax Pharmaceuticals, Inc. 股票老虎,Syndax Pharmaceuticals, Inc. 股票老虎国际,Syndax Pharmaceuticals, Inc. 行情,Syndax Pharmaceuticals, Inc. 股票行情,Syndax Pharmaceuticals, Inc. 股价,Syndax Pharmaceuticals, Inc. 股市,Syndax Pharmaceuticals, Inc. 股票价格,Syndax Pharmaceuticals, Inc. 股票交易,Syndax Pharmaceuticals, Inc. 股票购买,Syndax Pharmaceuticals, Inc. 股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}